Express News | Lyell Immunopharma Files Prospectus Related to Resale From Time to Time by Selling Stockholders of up to 37.5 Mln Shares of Common Stock - SEC Filing
The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts
Express News | HC Wainwright & Co. Reiterates Neutral on Lyell Immunopharma, Maintains $1 Price Target
Lyell Immunopharma Analyst Ratings
Mitchell Kapoor Maintains Hold Rating on Lyell Immunopharma Amid Promising IMPT-314 Results and Market Challenges
Positive Week for Lyell Immunopharma, Inc. (NASDAQ:LYEL) Institutional Investors Who Lost 26% Over the Past Year
